Accueil / Tag Archives: New-York (page 18)

Tag Archives: New-York

UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

Tuesday, September 10th 2019 at 12:00pm UTC Company to Also Participate in September Investor Conferences NEW YORK–(BUSINESS WIRE)– UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on September 24, 2019 in New York …

Plus »

Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

Tuesday, September 10th 2019 at 11:00am UTC NEW YORK–(BUSINESS WIRE)– THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE …

Plus »

Sensorion Announces Three Presentations at IEB 2019 in Padua

Wednesday, September 11th 2019 at 5:30am UTC An oral presentation in the session « Beyond the Device: New Therapeutic Approaches for Hearing Loss » on SENS-401 Two preclinical posters on ototoxicity MONTPELLIER, France–(BUSINESS WIRE)– Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of …

Plus »

Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

Tuesday, September 10th 2019 at 11:00am UTC —First Demonstration of Successful Engraftment of Gene Corrected Hematopoietic Stem Cells Without the Use of Conditioning— NEW YORK–(BUSINESS WIRE)– Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the publication of long-term data from the ongoing …

Plus »

Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA

Monday, September 9th 2019 at 10:00am UTC NEW YORK–(BUSINESS WIRE)– Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate …

Plus »

AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference

Monday, September 9th 2019 at 11:00am UTC ALAMEDA, Calif.–(BUSINESS WIRE)– AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced that founder and CEO Michael D. West, Ph.D. is presenting at the 21st Annual Rodman & Renshaw Global Investment Conference at the New …

Plus »

Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

Monday, September 9th 2019 at 12:00pm UTC Additionally, Pfizer Has Completed Enrollment of its Phase 3 Studies (NCT03828617, NCT03835975 and NCT03760146) for its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older NEW YORK–(BUSINESS WIRE)– Pfizer Inc. …

Plus »

Aptorum Group annonce le développement d’un médicament candidat microbien ciblant l’obésité et d’un médicament candidat réorienté ciblant le neuroblastome

Monday, September 9th 2019 at 10:35am UTC NEW YORK–(BUSINESS WIRE)– Aptorum Group Limited (Nasdaq : APM) ( » Aptorum Group « ), société biopharmaceutique axée sur le développement de nouveaux traitements pour répondre à des besoins médicaux non satisfaits à l’échelle mondiale, annonce le développement de deux médicaments candidats précliniques qui ciblent …

Plus »

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

Sunday, September 8th 2019 at 12:00pm UTC – 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint) – …

Plus »

Le Groupe Aptorum entame des études destinées à présenter une demande d’homologation pour sa petite molécule candidate ALS-4, pour le traitement d’infections causées par le staphylocoque doré, dont le SARM

Monday, September 9th 2019 at 10:00am UTC NEW YORK–(BUSINESS WIRE)– Aptorum Group Limited (Nasdaq: APM) (le « Groupe Aptorum »), une société pharmaceutique axée sur le développement de nouveaux traitements visant à répondre à des besoins médicaux mondiaux encore non-satisfaits, annonce avoir lancé des études d’approbation de drogue nouvelle (IND) pour ALS-4, …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.